CompanyPCVXNasdaqSan Carlos, CA

Vaxcyte, Inc.

Vaxcyte develops pneumococcal conjugate vaccines (PCVs) and other bacterial vaccines.

SEC EDGAR ClinicalTrials.gov vaxcyte.com

8-KSep 3Latest SEC filing, period to Aug 31

Sep 3Latest story

September 2026

Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timing

Sep 3Clinical readoutVaxcyte, Inc.

August 2026

Vaxcyte reports Q2 2026 results, OPUS Phase 3 trials fully enrolled, initiates VAX-A1 Phase 1

Aug 5Quarterly updateVaxcyte, Inc.

July 2026

Vaxcyte board sees director change as Lukatch retires, Markels joins

Jul 15PeopleVaxcyte, Inc.